Phthalocyanine–Peptide Conjugates for Epidermal Growth Factor Receptor Targeting
Four phthalocyanine (Pc)–peptide conjugates designed to target the epidermal growth factor receptor (EGFR) were synthesized and evaluated in vitro using four cell lines: human carcinoma A431 and HEp2, human colorectal HT-29, and kidney Vero (negative control) cells. Two peptide ligands for EGFR were...
Saved in:
Published in | Journal of medicinal chemistry Vol. 55; no. 8; pp. 3725 - 3738 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
26.04.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Four phthalocyanine (Pc)–peptide conjugates designed to target the epidermal growth factor receptor (EGFR) were synthesized and evaluated in vitro using four cell lines: human carcinoma A431 and HEp2, human colorectal HT-29, and kidney Vero (negative control) cells. Two peptide ligands for EGFR were investigated: EGFR-L1 and -L2, bearing 6 and 13 amino acid residues, respectively. The peptides and Pc-conjugates were shown to bind to EGFR using both theoretical (Autodock) and experimental (SPR) investigations. The Pc–EGFR-L1 conjugates 5a and 5b efficiently targeted EGFR and were internalized, in part due to their cationic charge, whereas the uncharged Pc–EGFR-L2 conjugates 4b and 6a poorly targeted EGFR maybe due to their low aqueous solubility. All conjugates were nontoxic (IC50 > 100 μM) to HT-29 cells, both in the dark and upon light activation (1 J/cm2). Intravenous (iv) administration of conjugate 5b into nude mice bearing A431 and HT-29 human tumor xenografts resulted in a near-IR fluorescence signal at ca. 700 nm, 24 h after administration. Our studies show that Pc–EGFR-L1 conjugates are promising near-IR fluorescent contrast agents for CRC and potentially other EGFR overexpressing cancers. |
---|---|
AbstractList | Four phthalocyanine (Pc)-peptide conjugates designed to target the epidermal growth factor receptor (EGFR) were synthesized and evaluated in vitro using four cell lines: human carcinoma A431 and HEp2, human colorectal HT-29, and kidney Vero (negative control) cells. Two peptide ligands for EGFR were investigated: EGFR-L1 and -L2, bearing 6 and 13 amino acid residues, respectively. The peptides and Pc-conjugates were shown to bind to EGFR using both theoretical (Autodock) and experimental (SPR) investigations. The Pc-EGFR-L1 conjugates 5a and 5b efficiently targeted EGFR and were internalized, in part due to their cationic charge, whereas the uncharged Pc-EGFR-L2 conjugates 4b and 6a poorly targeted EGFR maybe due to their low aqueous solubility. All conjugates were nontoxic (IC(50) > 100 μM) to HT-29 cells, both in the dark and upon light activation (1 J/cm(2)). Intravenous (iv) administration of conjugate 5b into nude mice bearing A431 and HT-29 human tumor xenografts resulted in a near-IR fluorescence signal at ca. 700 nm, 24 h after administration. Our studies show that Pc-EGFR-L1 conjugates are promising near-IR fluorescent contrast agents for CRC and potentially other EGFR overexpressing cancers. Four phthalocyanine (Pc)–peptide conjugates designed to target the epidermal growth factor receptor (EGFR) were synthesized and evaluated in vitro using four cell lines: human carcinoma A431 and HEp2, human colorectal HT-29, and kidney Vero (negative control) cells. Two peptide ligands for EGFR were investigated: EGFR-L1 and -L2, bearing 6 and 13 amino acid residues, respectively. The peptides and Pc-conjugates were shown to bind to EGFR using both theoretical (Autodock) and experimental (SPR) investigations. The Pc–EGFR-L1 conjugates 5a and 5b efficiently targeted EGFR and were internalized, in part due to their cationic charge, whereas the uncharged Pc–EGFR-L2 conjugates 4b and 6a poorly targeted EGFR maybe due to their low aqueous solubility. All conjugates were nontoxic (IC50 > 100 μM) to HT-29 cells, both in the dark and upon light activation (1 J/cm2). Intravenous (iv) administration of conjugate 5b into nude mice bearing A431 and HT-29 human tumor xenografts resulted in a near-IR fluorescence signal at ca. 700 nm, 24 h after administration. Our studies show that Pc–EGFR-L1 conjugates are promising near-IR fluorescent contrast agents for CRC and potentially other EGFR overexpressing cancers. |
Author | Vicente, M. Graça H Satyanarayana-Jois, Seetharama D Hu, Xiaoke Sehgal, Inder Ongarora, Benson G Fontenot, Krystal R |
Author_xml | – sequence: 1 givenname: Benson G surname: Ongarora fullname: Ongarora, Benson G – sequence: 2 givenname: Krystal R surname: Fontenot fullname: Fontenot, Krystal R – sequence: 3 givenname: Xiaoke surname: Hu fullname: Hu, Xiaoke – sequence: 4 givenname: Inder surname: Sehgal fullname: Sehgal, Inder email: vicente@lsu.edu – sequence: 5 givenname: Seetharama D surname: Satyanarayana-Jois fullname: Satyanarayana-Jois, Seetharama D – sequence: 6 givenname: M. Graça H surname: Vicente fullname: Vicente, M. Graça H email: vicente@lsu.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22468711$$D View this record in MEDLINE/PubMed |
BookMark | eNptkE1OwzAQhS1URH9gwQVQNkiwCNjjxHGXqGoLUiWqqqwj13HaREkcbEeoO-7ADTkJRi1dsZrR0zdP894Q9RrdKISuCX4gGMhjWQMmcRTtz9CAxIDDiOOohwYYA4TAgPbR0NoSY0wJ0AvUB4gYTwgZoNVy53ai0nIvmqJR359fS9W6IlPBRDdltxVO2SDXJpi2XjS1qIK50R9uF8yEdF5fKekP_LIWZqtc0Wwv0XkuKquujnOE3mbT9eQ5XLzOXyZPi1BEhLkw4WKMJU4g55uc0iTPuAQ2ZhEICZlK2JgLwRkH_zKJMc3iDLMxzpJNLlQMlI7Q3cG3Nfq9U9aldWGlqirRKN3ZlGCSJDGHOPbo_QGVRltrVJ62pqiF2Xso_a0wPVXo2ZujbbepVXYi_zrzwO0BENKmpe5M41P-Y_QD7FB6NQ |
CitedBy_id | crossref_primary_10_1002_pep2_24038 crossref_primary_10_1142_S1088424617500481 crossref_primary_10_1021_acsabm_3c01078 crossref_primary_10_1039_C9OB00731H crossref_primary_10_1039_C6OB00122J crossref_primary_10_1002_cmdc_202200506 crossref_primary_10_1142_S1088424616500188 crossref_primary_10_1007_s13238_019_0639_7 crossref_primary_10_1039_D0SM00428F crossref_primary_10_1002_chem_201706128 crossref_primary_10_1016_j_biocel_2019_105575 crossref_primary_10_1016_j_biomaterials_2022_121758 crossref_primary_10_1142_S1088424614500849 crossref_primary_10_1021_acsami_1c23740 crossref_primary_10_1021_acschemneuro_8b00083 crossref_primary_10_1016_j_jconrel_2022_12_015 crossref_primary_10_1111_cbdd_13125 crossref_primary_10_1016_j_jphotobiol_2014_09_002 crossref_primary_10_1142_S108842461250143X crossref_primary_10_1142_S1088424616500115 crossref_primary_10_1016_j_bios_2015_06_063 crossref_primary_10_1039_C6OB00099A crossref_primary_10_1007_s00775_017_1450_7 crossref_primary_10_1039_C9RA03911B crossref_primary_10_1517_13543776_2014_871527 crossref_primary_10_1002_pola_28929 crossref_primary_10_1016_j_bioorg_2021_104667 crossref_primary_10_1111_php_13234 crossref_primary_10_1016_j_jpba_2013_05_014 crossref_primary_10_1039_D0MD00284D crossref_primary_10_3390_ijms231710198 crossref_primary_10_1016_j_dyepig_2018_11_055 crossref_primary_10_1021_acs_jmedchem_8b01746 crossref_primary_10_1007_s10118_013_1242_7 crossref_primary_10_3390_catal8100480 crossref_primary_10_3390_pharmaceutics10010002 crossref_primary_10_1039_C4NR00595C crossref_primary_10_1016_j_xphs_2019_01_014 crossref_primary_10_1021_acs_molpharmaceut_1c00918 crossref_primary_10_1142_S1088424619300118 crossref_primary_10_1039_C7CS00554G crossref_primary_10_1016_j_cclet_2018_04_025 crossref_primary_10_1016_j_jconrel_2022_07_018 crossref_primary_10_1016_j_jphotobiol_2018_12_020 crossref_primary_10_1021_acs_inorgchem_7b00847 crossref_primary_10_1002_asia_201300039 crossref_primary_10_1016_j_phytol_2023_06_003 crossref_primary_10_1021_bc5001388 crossref_primary_10_1039_C7TB01233K crossref_primary_10_1016_j_colsurfb_2016_06_012 crossref_primary_10_1016_j_dyepig_2017_03_004 crossref_primary_10_1016_j_biomaterials_2016_12_010 crossref_primary_10_1039_c3dt50910a crossref_primary_10_1021_acs_jmedchem_3c01889 crossref_primary_10_1021_jacs_3c07687 crossref_primary_10_3390_molecules26041076 crossref_primary_10_1016_j_ijpharm_2016_09_071 crossref_primary_10_1016_j_synthmet_2012_07_028 crossref_primary_10_1021_acs_jmedchem_1c01505 crossref_primary_10_1016_j_dyepig_2014_11_002 crossref_primary_10_1021_acs_jmedchem_0c01677 crossref_primary_10_3390_molecules24040817 crossref_primary_10_1021_acs_molpharmaceut_6b00110 crossref_primary_10_1007_s10989_019_09824_4 crossref_primary_10_1021_acsomega_2c03407 crossref_primary_10_1016_j_ejmech_2013_04_038 crossref_primary_10_1038_onc_2016_522 crossref_primary_10_1016_j_cclet_2024_109910 crossref_primary_10_1007_s00894_021_05007_5 crossref_primary_10_1021_acs_bioconjchem_7b00211 crossref_primary_10_1142_S1088424617300014 crossref_primary_10_1021_acs_molpharmaceut_9b01043 crossref_primary_10_3390_molecules26030593 crossref_primary_10_1007_s00726_018_2616_5 |
Cites_doi | 10.1158/1078-0432.CCR-04-1902 10.1002/sca.4950230405 10.1002/cmdc.201100186 10.1016/j.bioorg.2006.11.005 10.1158/1078-0432.CCR-07-4926 10.1073/pnas.0912811107 10.1177/107327480701400313 10.1016/j.jim.2005.11.021 10.1093/jnci/90.12.889 10.1039/b917280g 10.1021/jm000527m 10.1158/1078-0432.CCR-06-1732 10.1142/S1088424604000325 10.1194/jlr.M800150-JLR200 10.1038/ncponc0881 10.1111/j.1365-2036.2007.03494.x 10.1016/j.tet.2010.02.079 10.1002/jcc.20634 10.1074/jbc.M007540200 10.1245/ASO.2006.05.052 10.1096/fj.05-4058com 10.1021/ja0482536 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B 10.1021/jm701050j 10.1634/theoncologist.9-1-58 10.1002/(SICI)1099-1409(200006/07)4:4<368::AID-JPP244>3.0.CO;2-6 10.1039/C1MD00232E 10.1073/pnas.75.7.3317 10.1074/jbc.M102225200 10.7150/thno/v01p0230 10.1096/fj.08-117002 10.1016/j.gie.2009.04.002 10.1142/S1088424604000374 10.1093/annonc/mdi006 10.1021/bc9005317 10.1016/j.ijpharm.2008.07.012 10.1007/BF01249659 10.1007/BF01741322 10.1023/A:1012313512797 10.1073/pnas.80.5.1337 10.1007/s00232-002-1015-7 10.1021/jm050893b 10.1517/13543784.17.10.1517 10.1038/sj.bjc.6600299 10.1093/oso/9780199632251.003.0011 10.1021/bc050057g 10.1016/j.addr.2003.08.015 10.1016/S1097-2765(03)00047-9 10.1021/bc060297b 10.18388/abp.2005_3443 |
ContentType | Journal Article |
Copyright | Copyright © 2012 American Chemical Society |
Copyright_xml | – notice: Copyright © 2012 American Chemical Society |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1021/jm201544y |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-4804 |
EndPage | 3738 |
ExternalDocumentID | 10_1021_jm201544y 22468711 a334620821 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: 8 P20GM103424-11 – fundername: NCI NIH HHS grantid: R21 CA139385 – fundername: NCRR NIH HHS grantid: 5P20RR016456-11 – fundername: NIGMS NIH HHS grantid: R25 GM069743 – fundername: NIGMS NIH HHS grantid: P20 GM103424 – fundername: NCRR NIH HHS grantid: P20 RR016456 |
GroupedDBID | - .K2 4.4 53G 55A 5GY 5RE 5VS 7~N AABXI ABFLS ABMVS ABOCM ABPTK ABUCX ACGFS ACJ ACS AEESW AENEX AFEFF ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 DU5 EBS ED ED~ EJD F5P GNL IH9 IHE JG JG~ K2 L7B LG6 P2P ROL TN5 UI2 VF5 VG9 W1F WH7 X XFK YZZ ZY4 --- -~X 6P2 AAHBH ABJNI ABQRX ABTAH ACGFO ADHLV AGXLV AHGAQ CGR CUPRZ CUY CVF ECM EIF GGK IH2 NPM XSW YQT AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-a416t-78a90c072f8bf337fd8c269642ac2de7698aa86821231503d5d0690d7bfae5233 |
IEDL.DBID | ACS |
ISSN | 0022-2623 |
IngestDate | Sat Aug 17 02:19:50 EDT 2024 Fri Aug 23 00:27:34 EDT 2024 Sat Sep 28 07:50:05 EDT 2024 Thu Aug 27 13:42:06 EDT 2020 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a416t-78a90c072f8bf337fd8c269642ac2de7698aa86821231503d5d0690d7bfae5233 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://europepmc.org/articles/pmc3523363?pdf=render |
PMID | 22468711 |
PQID | 1017758255 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_1017758255 crossref_primary_10_1021_jm201544y pubmed_primary_22468711 acs_journals_10_1021_jm201544y |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 7~N ACJ VG9 W1F ACS AEESW AFEFF .K2 ABMVS ABUCX IH9 BAANH AQSVZ ED~ UI2 |
PublicationCentury | 2000 |
PublicationDate | 2012-04-26 |
PublicationDateYYYYMMDD | 2012-04-26 |
PublicationDate_xml | – month: 04 year: 2012 text: 2012-04-26 day: 26 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of medicinal chemistry |
PublicationTitleAlternate | J. Med. Chem |
PublicationYear | 2012 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | 9637138 - J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 18426194 - J Med Chem. 2008 May 22;51(10):2915-23 19559426 - Gastrointest Endosc. 2009 Aug;70(2):197-200 20044619 - Anticancer Res. 2009 Dec;29(12):5077-82 17657253 - Nat Clin Pract Oncol. 2007 Aug;4(8):480-90 11472210 - J Med Chem. 2001 Aug 2;44(16):2565-74 11986789 - Br J Cancer. 2002 May 6;86(9):1518-23 16029027 - Bioconjug Chem. 2005 Jul-Aug;16(4):852-63 12620237 - Mol Cell. 2003 Feb;11(2):507-17 4313210 - Arch Gesamte Virusforsch. 1969;27(2):379-85 16448666 - J Immunol Methods. 2006 Feb 20;309(1-2):120-9 11534811 - Scanning. 2001 Jul-Aug;23(4):249-54 1760809 - Cancer Immunol Immunother. 1991;34(1):37-42 17279788 - Bioconjug Chem. 2007 Mar-Apr;18(2):410-20 20165809 - Org Biomol Chem. 2010 Mar 7;8(5):1160-72 11448953 - J Biol Chem. 2001 Sep 7;276(36):33869-74 18692120 - Int J Pharm. 2008 Nov 3;363(1-2):155-61 20387862 - Bioconjug Chem. 2010 May 19;21(5):828-35 17223161 - Bioorg Chem. 2007 Jun;35(3):205-20 16480271 - J Med Chem. 2006 Feb 23;49(4):1364-72 15746071 - Clin Cancer Res. 2005 Feb 15;11(4):1658-68 6298788 - Proc Natl Acad Sci U S A. 1983 Mar;80(5):1337-41 14755015 - Oncologist. 2004;9(1):58-67 18413814 - Clin Cancer Res. 2008 Apr 15;14(8):2253-62 18808311 - Expert Opin Investig Drugs. 2008 Oct;17(10):1517-31 16319141 - FASEB J. 2005 Dec;19(14):1978-85 14706445 - Adv Drug Deliv Rev. 2004 Jan 13;56(1):53-76 20217627 - Methods Mol Biol. 2010;627:249-60 15291531 - J Am Chem Soc. 2004 Aug 11;126(31):9506-7 21562630 - Theranostics. 2011 Apr 06;1:230-9 15598946 - Ann Oncol. 2005 Jan;16(1):102-8 12395282 - J Membr Biol. 2002 Oct 1;189(3):167-79 18469301 - J Lipid Res. 2008 Aug;49(8):1807-15 15990916 - Acta Biochim Pol. 2005;52(2):301-10 20080563 - Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1284-8 18081653 - Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:91-9 17615536 - Cancer Control. 2007 Jul;14(3):295-304 17085641 - Clin Cancer Res. 2006 Nov 1;12(21):6326-30 16614884 - Ann Surg Oncol. 2006 Jun;13(6):823-35 19124558 - FASEB J. 2009 May;23(5):1396-404 J Med Chem. 2012 Jun 14;55(11):5648 8822200 - Cell Growth Differ. 1996 Feb;7(2):173-8 11084031 - J Biol Chem. 2001 Feb 23;276(8):5836-40 17274016 - J Comput Chem. 2007 Apr 30;28(6):1145-52 21732537 - ChemMedChem. 2011 Sep 5;6(9):1715-26 356052 - Proc Natl Acad Sci U S A. 1978 Jul;75(7):3317-21 22308216 - Medchemcomm. 2012;3(2):179-194 Kawamoto T. (ref42/cit42) 1983; 80 Trivedi E. R. (ref55/cit55) 2010; 107 Sibrian-Vazquez M. (ref38/cit38) 2006; 49 Dougherty U. (ref20/cit20) 2008; 14 Song S. (ref26/cit26) 2009; 23 Kessel D. (ref54/cit54) 2004; 8 Berezov A. (ref37/cit37) 2001; 44 Komolov K. E. (ref36/cit36) 2010 Zuhorn I. S. (ref50/cit50) 2002; 189 Song S. X. (ref25/cit25) 2008; 363 Rao R. V. (ref53/cit53) 2001; 276 Huey R. (ref33/cit33) 2006; 28 Sibrian-Vazquez M. (ref48/cit48) 2005; 16 Erk P. (ref9/cit9) 2003; 19 Rocha-Lima C. M. (ref40/cit40) 2007; 14 Galizia G. (ref19/cit19) 2006; 13 Spernyak J. A. (ref57/cit57) 2010; 21 Dabrowski J. M. (ref58/cit58) 2011; 6 Ben-Hur E. (ref8/cit8) 2003; 19 Pandey R. K. (ref12/cit12) 2000; 4 Pellegrini R. (ref45/cit45) 1991; 34 Magné N. (ref46/cit46) 2002; 86 Liu T. M. (ref7/cit7) 2001; 23 Loeffler-Ragg J. (ref21/cit21) 2008; 17 Sibrian-Vazquez M. (ref28/cit28) 2007; 18 Dougherty T. J. (ref11/cit11) 1998; 90 Kimura M. (ref10/cit10) 2003; 19 Sharman W. M. (ref6/cit6) 2003; 15 Morris G. M. (ref32/cit32) 1998; 19 Sibrian-Vazquez M. (ref59/cit59) 2008; 51 Giannopoulou E. (ref47/cit47) 2009; 29 Haigler H. (ref43/cit43) 1978; 75 Molema G. (ref22/cit22) 2005; 52 Kantsevoy S. V. (ref4/cit4) 2009; 70 Meric-Bernstam F. (ref17/cit17) 2006; 12 Sibrian-Vazquez M. (ref39/cit39) 2010; 8 Macfarla D. (ref44/cit44) 1969; 27 Kiesslich R. (ref2/cit2) 2007; 4 Pérez-Soler R. (ref16/cit16) 2004; 9 Spano J.–P. (ref18/cit18) 2005; 16 Sharman W. M. (ref13/cit13) 2004; 56 Ferguson K. M. (ref34/cit34) 2003; 11 Brykina G. D. (ref30/cit30) 2001; 56 Gulli L. F. (ref41/cit41) 1996; 7 Li Z. (ref27/cit27) 2005; 19 Ongarora B. G. (ref29/cit29) 2012; 3 Dane K. Y. (ref23/cit23) 2006; 309 Sutcliffe M. J. (ref35/cit35) 1993 Futaki S. (ref49/cit49) 2001; 276 Savellano M. D. (ref14/cit14) 2005; 11 Zorlu Y. (ref31/cit31) 2010; 66 Leznoff C. C. (ref5/cit5) 1989; 1 Van den Broek F. J. (ref3/cit3) 2007; 26 Rothbard J. B. (ref51/cit51) 2004; 126 Jeong H. (ref56/cit56) 2011; 1 (ref1/cit1) 2011 Frochot C. (ref24/cit24) 2007; 35 Hudson R. (ref15/cit15) 2004; 8 He J. (ref52/cit52) 2008; 49 |
References_xml | – volume: 11 start-page: 1658 year: 2005 ident: ref14/cit14 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-04-1902 contributor: fullname: Savellano M. D. – volume: 23 start-page: 249 year: 2001 ident: ref7/cit7 publication-title: Scanning doi: 10.1002/sca.4950230405 contributor: fullname: Liu T. M. – volume: 19 start-page: 1 volume-title: The Porphyrin Handbook year: 2003 ident: ref8/cit8 contributor: fullname: Ben-Hur E. – volume: 6 start-page: 1715 issue: 9 year: 2011 ident: ref58/cit58 publication-title: ChemMedChem. doi: 10.1002/cmdc.201100186 contributor: fullname: Dabrowski J. M. – volume: 35 start-page: 205 year: 2007 ident: ref24/cit24 publication-title: Bioorg. Chem. doi: 10.1016/j.bioorg.2006.11.005 contributor: fullname: Frochot C. – volume: 14 start-page: 2253 year: 2008 ident: ref20/cit20 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-4926 contributor: fullname: Dougherty U. – volume: 107 start-page: 1284 issue: 4 year: 2010 ident: ref55/cit55 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0912811107 contributor: fullname: Trivedi E. R. – volume: 14 start-page: 295 issue: 3 year: 2007 ident: ref40/cit40 publication-title: Cancer Control doi: 10.1177/107327480701400313 contributor: fullname: Rocha-Lima C. M. – volume: 309 start-page: 120 year: 2006 ident: ref23/cit23 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2005.11.021 contributor: fullname: Dane K. Y. – volume: 90 start-page: 889 year: 1998 ident: ref11/cit11 publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/90.12.889 contributor: fullname: Dougherty T. J. – volume: 8 start-page: 1160 year: 2010 ident: ref39/cit39 publication-title: Org. Biomol. Chem. doi: 10.1039/b917280g contributor: fullname: Sibrian-Vazquez M. – volume: 44 start-page: 2565 year: 2001 ident: ref37/cit37 publication-title: J. Med. Chem. doi: 10.1021/jm000527m contributor: fullname: Berezov A. – volume: 12 start-page: 6326 year: 2006 ident: ref17/cit17 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-1732 contributor: fullname: Meric-Bernstam F. – volume: 8 start-page: 954 year: 2004 ident: ref15/cit15 publication-title: J. Porphyrins Phthalocyanines doi: 10.1142/S1088424604000325 contributor: fullname: Hudson R. – volume: 19 start-page: 151 volume-title: The Porphyrin Handbook year: 2003 ident: ref10/cit10 contributor: fullname: Kimura M. – volume: 49 start-page: 1807 issue: 8 year: 2008 ident: ref52/cit52 publication-title: J. Lipid Res. doi: 10.1194/jlr.M800150-JLR200 contributor: fullname: He J. – volume-title: American Cancer Society Detailed Guide year: 2011 ident: ref1/cit1 – volume: 4 start-page: 480 year: 2007 ident: ref2/cit2 publication-title: Nature Clin. Pract. Oncol. doi: 10.1038/ncponc0881 contributor: fullname: Kiesslich R. – volume: 26 start-page: 91 year: 2007 ident: ref3/cit3 publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2007.03494.x contributor: fullname: Van den Broek F. J. – volume: 66 start-page: 3248 year: 2010 ident: ref31/cit31 publication-title: Tetrahedron doi: 10.1016/j.tet.2010.02.079 contributor: fullname: Zorlu Y. – volume: 28 start-page: 1145 year: 2006 ident: ref33/cit33 publication-title: J. Comput. Chem. doi: 10.1002/jcc.20634 contributor: fullname: Huey R. – volume: 276 start-page: 5836 year: 2001 ident: ref49/cit49 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M007540200 contributor: fullname: Futaki S. – volume: 13 start-page: 823 year: 2006 ident: ref19/cit19 publication-title: Ann. Surg. Oncol. doi: 10.1245/ASO.2006.05.052 contributor: fullname: Galizia G. – volume: 19 start-page: 1978 year: 2005 ident: ref27/cit27 publication-title: FASEB J. doi: 10.1096/fj.05-4058com contributor: fullname: Li Z. – volume: 126 start-page: 9506 year: 2004 ident: ref51/cit51 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja0482536 contributor: fullname: Rothbard J. B. – volume: 19 start-page: 1639 year: 1998 ident: ref32/cit32 publication-title: J. Comput. Chem. doi: 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B contributor: fullname: Morris G. M. – volume: 51 start-page: 2915 year: 2008 ident: ref59/cit59 publication-title: J. Med. Chem. doi: 10.1021/jm701050j contributor: fullname: Sibrian-Vazquez M. – volume: 15 start-page: 1 volume-title: The Porphyrin Handbook year: 2003 ident: ref6/cit6 contributor: fullname: Sharman W. M. – volume: 9 start-page: 58 year: 2004 ident: ref16/cit16 publication-title: Oncologist doi: 10.1634/theoncologist.9-1-58 contributor: fullname: Pérez-Soler R. – volume: 29 start-page: 5077 issue: 12 year: 2009 ident: ref47/cit47 publication-title: Anticancer Res. contributor: fullname: Giannopoulou E. – volume: 4 start-page: 368 year: 2000 ident: ref12/cit12 publication-title: J. Porphyrins Phthalocyanines doi: 10.1002/(SICI)1099-1409(200006/07)4:4<368::AID-JPP244>3.0.CO;2-6 contributor: fullname: Pandey R. K. – volume: 3 start-page: 179 year: 2012 ident: ref29/cit29 publication-title: Med. Chem. Commun. doi: 10.1039/C1MD00232E contributor: fullname: Ongarora B. G. – volume-title: Methods Mol. Biol. year: 2010 ident: ref36/cit36 contributor: fullname: Komolov K. E. – volume: 75 start-page: 3317 issue: 7 year: 1978 ident: ref43/cit43 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.75.7.3317 contributor: fullname: Haigler H. – volume: 276 start-page: 33869 year: 2001 ident: ref53/cit53 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M102225200 contributor: fullname: Rao R. V. – volume: 1 start-page: 230 year: 2011 ident: ref56/cit56 publication-title: Theranostics doi: 10.7150/thno/v01p0230 contributor: fullname: Jeong H. – volume: 1 volume-title: Phthalocyanines: Properties and Applications year: 1989 ident: ref5/cit5 contributor: fullname: Leznoff C. C. – volume: 23 start-page: 1396 year: 2009 ident: ref26/cit26 publication-title: FASEB J. doi: 10.1096/fj.08-117002 contributor: fullname: Song S. – volume: 70 start-page: 197 issue: 2 year: 2009 ident: ref4/cit4 publication-title: Gastrointest. Endoscopy doi: 10.1016/j.gie.2009.04.002 contributor: fullname: Kantsevoy S. V. – volume: 8 start-page: 1009 year: 2004 ident: ref54/cit54 publication-title: J. Porphyrins Phthalocyanines doi: 10.1142/S1088424604000374 contributor: fullname: Kessel D. – volume: 19 start-page: 106 volume-title: The Porphyrin Handbook year: 2003 ident: ref9/cit9 contributor: fullname: Erk P. – volume: 16 start-page: 102 year: 2005 ident: ref18/cit18 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdi006 contributor: fullname: Spano J.–P. – volume: 21 start-page: 828 year: 2010 ident: ref57/cit57 publication-title: Bioconjugate Chem. doi: 10.1021/bc9005317 contributor: fullname: Spernyak J. A. – volume: 363 start-page: 155 year: 2008 ident: ref25/cit25 publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2008.07.012 contributor: fullname: Song S. X. – volume: 27 start-page: 379 issue: 2 year: 1969 ident: ref44/cit44 publication-title: Archiv. Ges. Virusforsch doi: 10.1007/BF01249659 contributor: fullname: Macfarla D. – volume: 34 start-page: 37 issue: 1 year: 1991 ident: ref45/cit45 publication-title: Cancer Immunol. Immunother. doi: 10.1007/BF01741322 contributor: fullname: Pellegrini R. – volume: 56 start-page: 940 year: 2001 ident: ref30/cit30 publication-title: J. Anal. Chem. doi: 10.1023/A:1012313512797 contributor: fullname: Brykina G. D. – volume: 80 start-page: 1337 issue: 5 year: 1983 ident: ref42/cit42 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.80.5.1337 contributor: fullname: Kawamoto T. – volume: 189 start-page: 167 issue: 3 year: 2002 ident: ref50/cit50 publication-title: J. Membr. Biol. doi: 10.1007/s00232-002-1015-7 contributor: fullname: Zuhorn I. S. – volume: 49 start-page: 1364 year: 2006 ident: ref38/cit38 publication-title: J. Med. Chem. doi: 10.1021/jm050893b contributor: fullname: Sibrian-Vazquez M. – volume: 17 start-page: 1517 year: 2008 ident: ref21/cit21 publication-title: Expert Opin. Invest. Drugs doi: 10.1517/13543784.17.10.1517 contributor: fullname: Loeffler-Ragg J. – volume: 86 start-page: 1518 year: 2002 ident: ref46/cit46 publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6600299 contributor: fullname: Magné N. – start-page: 359 volume-title: NMR of Macromolecules: A Practical Approach year: 1993 ident: ref35/cit35 doi: 10.1093/oso/9780199632251.003.0011 contributor: fullname: Sutcliffe M. J. – volume: 7 start-page: 173 issue: 2 year: 1996 ident: ref41/cit41 publication-title: Cell Growth Differ. contributor: fullname: Gulli L. F. – volume: 16 start-page: 852 issue: 4 year: 2005 ident: ref48/cit48 publication-title: Bioconjugate Chem. doi: 10.1021/bc050057g contributor: fullname: Sibrian-Vazquez M. – volume: 56 start-page: 53 year: 2004 ident: ref13/cit13 publication-title: Adv. Drug Delivery Rev. doi: 10.1016/j.addr.2003.08.015 contributor: fullname: Sharman W. M. – volume: 11 start-page: 507 year: 2003 ident: ref34/cit34 publication-title: Mol. Cell doi: 10.1016/S1097-2765(03)00047-9 contributor: fullname: Ferguson K. M. – volume: 18 start-page: 410 year: 2007 ident: ref28/cit28 publication-title: Bioconjugate Chem. doi: 10.1021/bc060297b contributor: fullname: Sibrian-Vazquez M. – volume: 52 start-page: 301 year: 2005 ident: ref22/cit22 publication-title: Acta Biochim. Pol. doi: 10.18388/abp.2005_3443 contributor: fullname: Molema G. |
SSID | ssj0003123 |
Score | 2.4173722 |
Snippet | Four phthalocyanine (Pc)–peptide conjugates designed to target the epidermal growth factor receptor (EGFR) were synthesized and evaluated in vitro using four... Four phthalocyanine (Pc)-peptide conjugates designed to target the epidermal growth factor receptor (EGFR) were synthesized and evaluated in vitro using four... |
SourceID | proquest crossref pubmed acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 3725 |
SubjectTerms | Animals Cercopithecus aethiops Colorectal Neoplasms - diagnosis Fluorescent Dyes - metabolism HT29 Cells Humans Indoles - metabolism Ligands Mice Mice, Nude Models, Molecular Oligopeptides Peptides - chemistry Peptides - metabolism Receptor, Epidermal Growth Factor - metabolism Vero Cells |
Title | Phthalocyanine–Peptide Conjugates for Epidermal Growth Factor Receptor Targeting |
URI | http://dx.doi.org/10.1021/jm201544y https://www.ncbi.nlm.nih.gov/pubmed/22468711 https://search.proquest.com/docview/1017758255 |
Volume | 55 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3JTsMwEB0VOMCFfSmbzKKempI4reMcUaEgJFAFReqtsmNbFUuKaHooJ_6BP-RLGCdNAUHh5kNsWR7b815m_AbgUCquajrijvEkd6rS444wrnIMo8a4VNVCz75Gvrxi57fVi3atXYCDCRF86h3dPdK0UtZwCmZogIfC4p_6zfi69T3q55LgFJ15Lh_0tat1PVH_u-uZgCdTv9JYgJP8dU6WTnJfGSSyEr38FGv8a8qLMD_CleQ42whLUNDxMszW83Juy1BqZiLVwzJpfb656pdJiTQ_5auHK3Dd7CZdgT5uKGKEoO-vb02b-aI0qffiu4H97dYnCHXJqS0uix0fyBly-aRLGmntHoJIFDtgo5VmmaNvXIXbxmmrfu6MKi84AgFa4gRchG7kBtRwaXw_MIpHlIXIVURElQ5YyIXgjFu_h4jSVzVlFY9VII3QSG39NZiOe7HeACKZlSTzmca7pBoxRDPKhkqDULhMcKmKsIum6YxOTr-TBsUpkpJ8DYuwn1ut85QpcPz20V5uzw6uqw16iFj3BnY8L0BOhMypCOuZocfDWDE9JIze5n9z2II5bFEbRaJsG6aT54HeQTCSyN10M34Aim7ZAw |
link.rule.ids | 315,783,787,2772,27088,27936,27937,57066,57116 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LTtwwFL0qdAEb2vIcysMgxIoMiTNxnGU1YjptAY1gkNhFdmxrxCODSGYxXfUf-of9Eq6dCQMIRHdRFFtXtpNzTq59LsCeVFxFOuOeCST3WjLgnjC-8gyjxvhURUlgTyOfnLLuRevnZXQ5scmxZ2EwiAJ7KlwSf-ouEBxe3VJXMGs8Ax-jGIHS0qD2-eNXNwxoWDuDU8T02kXoaVOLQFnxHIHeoJUOXjqfqjpFLjC3q-S6OSplM_v9wrPx_yL_DAsTlkm-VcviC3zQ-SLMtevibouw36ssq8cHpD89gVUckH3Sm5pZj5fgrDcoBwIRbyxyJKT__vzt2X0wSpP2ML8a2Z9wBUHiS45sqVlseEO-o7IvB6TjKvkQ5KXYAC_6bs85IuUyXHSO-u2uN6nD4Amka6UXc5H4mR9Tw6UJw9gonlGWoHIRGVU6ZgkXgjNuURD5ZagiZf2PVSyN0Ch0wxWYzYe5XgMimTUoC5nGL0srY8htlE2cxonwmeBSNWALhzCdvEdF6lLkFCVKPYYN2K0nL72r_Dhee2inntYUx9WmQESuhyPbXxCjQkId1YDVar4fu7HWeigfg_X3YtiGuW7_5Dg9_nH66yvM411q80uUbcBseT_Sm0hTSrnl1ucDVvnhaA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NT9wwEB1RkCgXvtrShQIGVZwITZyN4xzRluWbRu0icYvs2NaKtllEsoflxH_gH_aXdOxNFqha0VsUxdbIY3vey9hvAD5KxVWkc-6ZQHKvLQPuCeMrzzBqjE9VlAT2NvL5BTu6bJ9cRVc1UbR3YdCIEnsqXRLfruobZWqFgeDT9U_qimaNXsFMFAcuLbvf-TbZecOAho06OMW43igJPW1qo1BePo9C_4CWLsR0F-DLxDh3suT73rCSe_ndH7qN_2_9IszXaJPsj6fHEkzpYhled5oib8uwk46lq0e7pPd4E6vcJTskfRS1Hr2Br2m_6guMfCNRIDD9df-Q2vMwSpPOoLge2p9xJUEATA5syVls-IMcIsOv-qTrKvoQxKfYAB967uw5Rsy3cNk96HWOvLoegycQtlVezEXi535MDZcmDGOjeE5ZggxG5FTpmCVcCM64jYaIM0MVKauDrGJphEbCG76D6WJQ6PdAJLNCZSHTuMO0c4YYR9kEapwInwkuVQs2cBizej2VmUuVU6QqzRi2YLtxYHYz1uX420dbjWszHFebChGFHgxtf0GMTAn5VAtWxj6fdGMl9pBGBqsv2bAJs-nnbnZ2fHG6BnP4kto0E2UfYLq6Hep1RCuV3HBT9DevwOPi |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phthalocyanine%E2%80%93Peptide+Conjugates+for+Epidermal+Growth+Factor+Receptor+Targeting&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Ongarora%2C+Benson+G&rft.au=Fontenot%2C+Krystal+R&rft.au=Hu%2C+Xiaoke&rft.au=Sehgal%2C+Inder&rft.date=2012-04-26&rft.pub=American+Chemical+Society&rft.issn=0022-2623&rft.eissn=1520-4804&rft.volume=55&rft.issue=8&rft.spage=3725&rft.epage=3738&rft_id=info:doi/10.1021%2Fjm201544y&rft.externalDocID=a334620821 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon |